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Rhomboid proteases are integral membrane en-
zymes that regulate cell signaling, adhesion, and
organelle homeostasis pathways, making substrate
specificity a key feature of their function. Inter-
estingly, we found that perturbing the membrane
pharmacologically in living cells had little effect on
substrate processing but induced inappropriate
cleavage of nonsubstrates by rhomboid proteases.
A subclass of drugs known to modulate g-secretase
activity acted on the membrane directly and induced
nonsubstrate cleavage by rhomboid proteases but
left true substrate cleavage sites unaltered. These
observations highlight an active role for the mem-
brane in guiding rhomboid selectivity and caution
that membrane-targeted drugs should be evaluated
for cross-activity against membrane-resident en-
zymes that are otherwise unrelated to the intended
drug target. Furthermore, some g-secretase-modu-
lating activity or toxicity could partly result from
global membrane effects.
INTRODUCTION
Four families of multispanning membrane proteins have been
described with protease active sites that lie inside the cell mem-
brane (Manolaridis et al., 2013; Urban, 2013). These widespread
enzymes are being implicated in a growing spectrum of diseases
ranging from pathogen infection (Urban, 2009) to Alzheimer’s
disease (De Strooper and Annaert, 2010; Golde et al., 2013)
and are being intensively pursued as therapeutic targets. The
leading target is g-secretase, an aspartyl membrane protease
complex that generates the amyloid-b peptide that aggregates
into senile plaques in Alzheimer’s disease patients (De Strooper
and Annaert, 2010; Golde et al., 2013). Its substrate repertoire
is thought to comprise >100 proteins (Hemming et al., 2008),
earning g-secretase the moniker ‘‘proteasome of the mem-
brane’’ (Kopan and Ilagan, 2004).Cell ReThis broad client repertoire presents challenges to therapeu-
tic intervention because some substrates, especially the Notch
receptor, play ongoing signaling roles in adults (De Strooper
et al., 1999). Inhibition strategies with compounds that block
its protease activity are being replaced by allosteric modulation
strategies (Golde et al., 2013). This innovative approach uses
drugs that allow proteolysis to proceed but cause shifts in sites
of cleavage, or their proportions, away from the cytotoxic forms
of amyloid-b (Ebke et al., 2011; Fraering et al., 2004; Jumpertz
et al., 2012; Ohki et al., 2011; Weggen et al., 2001, 2003). The
precise mechanism of these modulators remains incompletely
understood, but it is important to resolve this fully because
drug regimens to treat Alzheimer’s disease will likely need to
be sustained for years if not for the life of the patient (De Strooper
and Annaert, 2010; Golde et al., 2013).
Rhomboid proteases, in contrast to g-secretase, are unre-
lated intramembrane serine proteases that are conserved in
nearly all organisms (Bergbold and Lemberg, 2013; Urban and
Dickey, 2011). Their roles in the malaria parasite are known to
be essential (Lin et al., 2013) and are thus widely considered
to be prime candidates for next-generation antiparasitic drugs.
The substrate specificity of rhomboid proteases is one hallmark
that distinguishes them from g-secretase. This selectivity was
thought to result only from sequence-specific binding of sub-
strates (Strisovsky et al., 2009), as occurs with other selective
proteases (Ng et al., 2009; Schechter, 2005). More recent spec-
troscopic (Moin and Urban, 2012) and kinetic (Dickey et al.,
2013) investigations suggest a driving role for substrate trans-
membrane dynamics in directing specificity, with less contribu-
tion from sequence binding. This model posits that rhomboid
proteases patrol the membrane, looking for transmembrane
helices that are unstable when they enter its active site and
are no longer supported by the membrane. A shift away from
an intrinsically stable helix toward a dynamic chain, coupled
with the availability of small residues to avoid steric clash in
the active site, leads to proteolysis.
To understand rhomboid protease mechanism and their roles
in the cell, and to ultimately achieve therapeutic targeting, it is
important to clarify precisely how they discriminate between
substrates and nonsubstrates. We therefore sought to test un-
der cellular conditions whether the membrane plays an activeports 8, 1241–1247, September 11, 2014 ª2014 The Authors 1241
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Figure 1. Perturbing the Membrane Pro-
vokes Nonsubstrate Cleavage by Rhomboid
(A) Treating transfected HEK293 cells with the
membrane-altering agents lyso-PC (lyP) or mbCD
(CD) induced cleavage (*) of GFP-APP-FLAG
(containing the last 99 APP residues) and Delta-
FLAG (right panel) by the cell-surface-localized
DmRho4 (Dm) and human RHBDL2 (Hs). No
cleavage was induced when the catalytic serine
of DmRho4 was mutated to alanine (SA). Cleavage
of GFP-APP+Spi7-FLAG by DmRho4 was not
perturbed by pharmacological treatment.
(B)Cleavage siteofGFP-APP-FLAGupon treatment
of cells with lyso-PC. The sequence shown starts
at the first transmembrane residue (glycine 700).
(C) APP-T714I was not cleaved by DmRho4,
except upon treatment, albeit at lower levels
(isoleucines near the cleavage site are often not
tolerated well by rhomboid).
(D) Effect of lysolipid acyl chain length (natural mix,
14, 16, 18), short-chain fatty acid DLPC, and
headgroup (lyPE, lyso-phosphatidylethanolamine)
on stimulating APP cleavage by DmRho4.
(E) Quantification (mean ± SD) of the effects of
lyso-PC and mbCD treatment on the cleavage of
GFP-APP-FLAG versus GFP-APP+Spi7-FLAG.
Note that since no APP cleavage could be de-
tected in untreated cells, the fold increase upon
treatment represents a minimum relative to west-
ern background.
(F) Effect of R-flurbiprofen (RFl), lyso-PC (ly)
and mbCD (CD) treatments on TatA, Spitz, and
APP+Spi7 cleavage.role in guiding proteolytic specificity, rather than rhomboid
relying on sequence incompatibility of nonsubstrates alone.
If the membrane helps to direct selectivity, then conditions
could exist that would allow wild-type rhomboid proteases to
cleave wild-type nonsubstrates simply by virtue of changes in
the membrane. We evaluated this possibility in living cells
and further discovered that a subset of drugs known to modu-
late g-secretase activity also induce rhomboid cleavage of
nonsubstrates.
RESULTS
Perturbing the Membrane Induces Rhomboid Proteases
to Cleave Nonsubstrates
Our goal in this work was to alter the cell membrane of living cells
and determine whether rhomboid proteases lose specificity.
Although membranes are composed of hundreds of different
lipid species, prior experiments suggested that altering the lipid
composition changes the levels of protease activity but pre-
serves both substrate and cleavage site specificity (Moin and
Urban, 2012; Urban and Wolfe, 2005). Instead, the physical
properties of the membrane are more likely to be important for
directing substrate specificity.
Compounds that add or remove lipids from the membrane
cause mechanical changes: treating cells with low concentra-
tions of exogenous phospholipids results in their rapid insertion1242 Cell Reports 8, 1241–1247, September 11, 2014 ª2014 The Auinto the outer leaflet of the membrane but slow flipping into the
inner leaflet, thereby creating a ‘‘transverse phospholipid imbal-
ance’’ between the leaflets (Bettache et al., 2003). Previous
studies have analyzed this phenomenon, but although the
ensuing cell-shape changes have proven useful for studying
cell locomotion (Bettache et al., 2003; Raucher and Sheetz,
2000), they have not been evaluated for effects on membrane
enzyme function. Therefore, these compounds might afford the
opportunity to alter the physical nature of the membrane phar-
macologically in living cells and evaluate whether this leads to
inappropriate nonsubstrate cleavage by rhomboid proteases.
Notably, both amyloid-b precursor protein (APP) and the
Notch receptor ligand Delta have been extensively studied and
are known not to be rhomboid substrates (Moin and Urban,
2012). We focused on human RHBDL2 and Drosophila Rho4
rhomboid proteases because they are localized to the cell
surface, where both APP and Delta function and where mem-
brane-altering agents have clear effects. Treating living human
cells with lyso-phosphatidylcholine (lyso-PC) or depleting
cholesterol with methyl-b-cyclodextrin (mbCD) induced cleav-
age of GFP-APP-FLAG or Delta-FLAG constructs by rhomboid
proteases (Figure 1A). Cleavage was specific to rhomboid prote-
olysis, since treating cells with these agents did not induce any
cleavage with an inactive mutant of rhomboid. Moreover, map-
ping the induced cleavage sites by mass spectrometry revealed
them to be intramembrane sites (Figure 1B). APP is known tothors
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C Figure 2. A Subset of NSAIDs Induces
Cleavage of Nonsubstrates by Rhomboid
Proteases
(A and B) Treating transfected HEK293 cells with
lyso-PC (lyP), mbCD (CD) or R-flurbiprofen (RFl)
induced cleavage (*) of GFP-APP-FLAG (A) and
Delta-FLAG (B) by DmRho4 or human RHBDL2. No
cleavage was induced when the catalytic serine
was mutated to alanine (SA). Cleavage of GFP-
APP+Spi7-FLAG was not perturbed by pharma-
cological treatment.
(C) Effect of R-flurbiprofen, flurbiprofen, ibuprofen,
indomethacin, aspirin, naproxen, and sulindac
sulfide on GFP-APP-FLAG versus GFP-APP+Spi7-
FLAG cleavage by DmRho4 in transfected HEK293
cells. Induced cleavage of GFP-APP-FLAG is
marked by an asterisk (*).dimerize, but its induced cleavage by rhomboid did not result
from the possibility of disrupting its TM dimer, because a familial
Alzheimer’s disease mutation that strongly reduces dimerization
by 38-fold (Gorman et al., 2008) could not be cleaved by rhom-
boid except upon treatment with membrane-altering agents
(Figure 1C). Therefore, cleavage of nonsubstrates by rhomboid
proteases can be induced by altering the physical state of the
membrane.
Physical Changes in the Membrane Relax Rhomboid
Specificity
The characteristics of inducing nonsubstrate processing sug-
gested that a lipid imbalance between membrane leaflets
was indeed selectively relaxing rhomboid specificity. Varying
the acyl chain length of lyso-PC had no effect on the level
of APP cleavage, whereas changing the headgroup to ethanol-
amine decreased potency 4-fold (Figure 1D). Even the short-
chain phospholipid dilauroylphosphatidylcholine (DLPC) could
induce APP cleavage, although this required 20-fold more
DLPC than lyso-PC. These features are consistent with induc-
tion of a lipid imbalance between the leaflets, since lysophos-
pholipids, which are extraordinarily slow in flipping to the
inner leaflet (Bhamidipati and Hamilton, 1995), were particu-
larly effective at inducing nonsubstrate cleavage, and potency
was dependent on the headgroup rather than the acyl-chain
length.
Second, the inducing effect selectively relaxed the specificity
of rhomboid intramembrane proteolysis rather than simply stim-
ulating proteolysis overall. Treating cells with lyso-PC or mbCD
resulted in >37-fold more GFP-APP-FLAG cleavage, whereas
cleavage of GFP-APP+Spi7-FLAG (an efficient substrate that
is >98% identical to GFP-APP-FLAG) increased by <2-fold
(Figure 1E). Moreover, natural substrates that are cleaved in-
efficiently (Dickey et al., 2013; Moin and Urban, 2012), like
Drosophila Spitz, could have their cleavage modestly stimulatedCell Reports 8, 1241–1247, Seby perturbing the membrane, in contrast
to the highly efficient substrates GFP-
APP+Spi7-FLAG and GFP-TatA-FLAG
(Figure 1F). Taken together, these experi-
ments reveal that cleavage of nonsub-strates by rhomboid proteases in living cells can be provoked
by perturbing the membrane.
g-Secretase-Modulating NSAIDs Induce Nonsubstrate
Cleavage by Rhomboid Proteases
Nonsteroidal anti-inflammatory drugs (NSAIDs) modulate g-sec-
retase by shifting the site of cleavage in substrates (Ebke et al.,
2011; Fraering et al., 2004; Jumpertz et al., 2012; Ohki et al.,
2011; Weggen et al., 2001, 2003). Since NSAIDs resemble
agents that conceivably could be active at interfacial regions of
membranes, we were intrigued to examine whether they could
induce nonsubstrate cleavage by rhomboid. We first tested
R-flurbiprofen (Tarenflurbil) at 0.5 mM, which is comparable to
the concentrations measured in the serum of patients (up to
0.483 mM) undergoing clinical trials (Eriksen et al., 2003).
Despite excellent evidence that NSAIDs target g-secretase
and/or APP (Ebke et al., 2011; Fraering et al., 2004; Jumpertz
et al., 2012; Kukar et al., 2008; Ohki et al., 2011; Weggen et al.,
2003), we found that R-flurbiprofen was also a strong inducer
of GFP-APP-FLAG (Figure 2A) and Delta-FLAG (Figure 2B)
cleavage by rhomboid, and modestly stimulated Spitz cleavage
while leaving GFP-APP+Spi7-FLAG and GFP-TatA-FLAG cleav-
age unaffected (Figure 1F). Importantly, stimulation of nonsub-
strate cleavage did not result fromCOX-2 inhibition, the intended
NSAID target, because the R-enantiomer of flurbiprofen that is
ineffective against COX-2 was at least as potent as the racemic
R/S mixture in inducing nonsubstrate cleavage (Figure 2C). In
fact, the effect was quantitatively and qualitatively comparable
to that elicited by lyso-PC and mbCD on two different substrates
by two different rhomboid enzymes (Figures 2A and 2B).
However, although NSAIDs shift the cleavage site of both g-
secretase (Ebke et al., 2011; Fraering et al., 2004; Jumpertz
et al., 2012; Ohki et al., 2011; Weggen et al., 2001, 2003) and
the related signal peptide peptidase (Sato et al., 2006), the cleav-
age site in natural rhomboid substrates, as a rule, did not shiftptember 11, 2014 ª2014 The Authors 1243
Figure 3. NSAIDs Do Not Shift the Cleavage Site of Rhomboid Substrates
Site ofDrosophilaGFP-Spitz-FLAG cleavage by DmRho4 (DmR) and human RHBDL2 (HsR) in mammalian cells mapped bymass spectrometry. Uncleaved Spitz
is demarcated with a white triangle (quadruple-charged species); the cleavage peak highlighted by blue asterisks appeared only when rhomboid was present.
Spitz was used as the substrate because it contains at least two other sites to which cleavage can readily shift (Moin and Urban, 2012).(Figure 3). Yet within a spectrum of seven commonly used
NSAIDs, primarily those known tomodulate g-secretase (Eriksen
et al., 2003; Fraering et al., 2004; Golde et al., 2013; Weggen
et al., 2001), including flurbiprofen, sulindac sulfide, and indo-
methacin, were effective at inducing rhomboid proteolysis of
nonsubstrates. In contrast, aspirin, ibuprofen, and naproxen
(Aleve) had weak effects (Figure 2C). Therefore, in addition to
treating with lyso-PC and mbCD, perturbing the cell membrane
with drugs is sufficient to trigger inappropriate cleavage of non-
substrates by rhomboid proteases in living cells.
Direct but Selective Membrane Perturbation Erodes
Rhomboid Specificity
Although we suspected that NSAIDs could exert physical effects
on cell membranes, it is important to note that most biophysical
analyses supporting this notion were not conducted under mild
conditions typical of cell culture (Boggara et al., 2012). Therefore,
we specifically assessed whether the low NSAID concentrations
that we used in our cell-culture experiments could exert effects
directly on membranes under physiological buffer and pH condi-
tions. Using differential scanning calorimetry (DSC), we
measured the major transition temperature (Tm) of membranes
comprised of phosphatidylcholine, the major constituent of
eukaryotic membranes, as a sensitive reporter of any physical
changes caused by NSAIDs (Figure 4A). All NSAIDs that
triggered nonsubstrate processing by rhomboid proteases
decreased the membrane Tm, confirming that these agents, in
low doses and under physiological conditions, have physical
effects directly on the membrane.
Finally, we examined whether other drugs that interact with
membranes could also relax rhomboid substrate specificity if
presented at sufficiently high doses. The non-NSAID ‘‘inverse
g-secretase modulator’’ fenofibrate (Tricor), which is clinically1244 Cell Reports 8, 1241–1247, September 11, 2014 ª2014 The Auused to treat cardiovascular disease and was found to elevate
amyloid-b42 levels (Leuchtenberger et al., 2006), was unable
to provoke nonsubstrate processing (Figure 4B) even when
presented at concentrations that resulted in high cytotoxicity
(Figure 4C). Similarly, two membranotrophic antibiotics, Irgasan
and triclocarban (Orsi et al., 2011), also did not provoke nonsub-
strate processing even at concentrations that resulted in high
cytotoxicity. Interestingly, sulindac sulfone, which is a COX-inac-
tive oxidative metabolite of sulindac (Weggen et al., 2001), was
more effective at provoking nonsubstrate processing than the
active metabolite sulindac sulfide, but had no cytotoxic effects
under conditions in which sulindac sulfide killedmost of the cells.
Therefore, only a subset of drugs that directly affect the mem-
brane selectively diminish the ability of rhomboid proteases to
distinguish substrates from nonsubstrates.
DISCUSSION
While probing the mechanism of rhomboid specificity, we
discovered that treating cells with membrane-altering agents
triggers inappropriate intramembrane proteolysis of nonsub-
strates by rhomboid proteases. Two significant implications
emerge from these findings:
First, these observations indicate that the membrane is a
direct and active participant in substrate discrimination beyond
just serving as a passive environment in which protease and
substrate reside. Other substrate-specific proteases bind their
substrates in a sequence-specific manner as a means of
achieving selectivity (Ng et al., 2009; Schechter, 2005). The abil-
ity to induce cleavage of nonsubstrates by altering the mem-
brane emphasizes that protein binding to rhomboid is not the
main feature of how substrates are selected. This is consistent
with kinetic and binding studies that revealed a very low affinitythors
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Figure 4. NSAIDs Directly but Selectively Alter the Cell Membrane to
Induce Nonsubstrate Cleavage
(A) DSC was used to measure the major transition temperature of DMPC
membranes in PBS with or without the indicated drugs. The unperturbed Tm of
23.18C agreed very well with prior studies (Caffrey and Hogan, 1992). Shown
are the mean Tm values (red line) ± SD (blue lines) and corresponding p values
(n = 3–7 measurements per condition).
(B) Induction of rhomboid cleavage of GFP-APP-FLAG by a variety of mem-
brane-acting drugs as revealed by western analysis. The induced cleavage
band is marked by a red asterisk (*).
(C) Quantification of cell viability following 24 hr of treatment with the indicated
compounds. Red bars indicate compounds that could not induce non-
substrate cleavage, and green bars indicate those that could. Error bars
indicate ± SD (n = 3–9 measurements per condition).
Cell Re(200 mM Kd) for true substrates (Dickey et al., 2013). Instead,
spectroscopic studies indicate that helical instability of trans-
membrane segments, which are conformationally responsive
to the membrane environment (Moin and Urban, 2012), is the
main feature that rhomboid enzymes use to identify substrates.
As such, the ultimate ability of rhomboid proteases to discrimi-
nate substrates from nonsubstrates depends on the membrane
itself enforcing strict rules for substrate cleavage.
Although the intended advantage of our cell-based approach
is to enable the study of enzymes/substrates under physiological
conditions, this complex system makes it difficult to decipher
how these agents alter the membrane to bypass the normal sub-
strate-discrimination process. The decrease in membrane Tm
established that NSAIDs act directly on the membrane, but this
sensitive but global parameter cannot reveal precisely how the
protease is ultimately affected to induce cleavage of nonsub-
strates. This is an interesting but challenging area for future
investigation, and computational approaches with rhomboid
proteases in particular hold great promise for revealing the un-
derlying basis (Bondar et al., 2009; Zhou et al., 2012). However,
only recently have molecular-dynamics simulations been con-
ducted with membrane-active compounds such as cryopreser-
vatives and NSAIDs (Boggara et al., 2012; Orsi et al., 2011),
and none have yet explored the ensuing effect on complex
(physiological) lipid mixtures or on enzymes within membranes.
We hope that our observations will provide a motivation for
undertaking such challenging studies.
Second, particularly intriguing and potentially useful is our
discovery that compounds known to modulate g-secretase ac-
tivity (De Strooper and Annaert, 2010; Ebke et al., 2011; Eriksen
et al., 2003; Fraering et al., 2004; Golde et al., 2013; Jumpertz
et al., 2012; Kukar et al., 2008; Ohki et al., 2011) also affect rhom-
boid proteolysis. This observation raises the possibility that the
holistic effect of g-secretase modulation may also involve simul-
taneous changes in the cell membrane. Indeed, although rhom-
boid proteases share no sequence similarity with g-secretase, a
similar (albeit not identical) spectrum of NSAIDs induced cleav-
age of several unrelated proteins by rhomboid proteases.
More directly, these observations indicate that the possibility
of a cross-reaction even with unrelated membrane enzymes,
such as rhomboid proteases, should be considered when
designing modulation strategies for Alzheimer’s disease. The
ability of these agents to trigger cleavage of nonsubstrates by
rhomboid proteases indicates that modulation strategies could
have unintended side effects. Nevertheless, it is worth clarifying
two points:
First, we used APP and Delta as two different reporters to
reveal nonsubstrate processing activity by rhomboid proteases,
but potential side effects may not necessarily come from either
one. Indeed, membrane-targeting agents will likely induce cleav-
age of additional nonsubstrates, although which ones or how
many will likely depend on the cell type or disease state. More-
over, in addition to the cell-surface enzymes that we studied,
some drugs, including NSAIDs, are also likely to cross mem-
branes and affect rhomboid proteases in internal organelles.
One organelle that deserves particular attention is the mitochon-
drion, in which a rhomboid protease is thought to switch sub-
strates to trigger mitophagy and/or apoptosis upon damageports 8, 1241–1247, September 11, 2014 ª2014 The Authors 1245
(Chan and McQuibban, 2013). This delicate substrate balance
could be particularly sensitive to membrane alterations, with
implications for Parkinson’s disease.
Ultimately determining which proteins can be pharmacologi-
cally induced to be cut is also unlikely to be sufficient to predict
which will produce phenotypes, since many proteases generate
‘‘bystander’’ cuts—cleavages that occur under physiological
conditions yet seem inconsequential to cell function (Plasman
et al., 2011). Even finding the most abundant cut proteins does
not guarantee that one will be able to identify the basis of a
potential side effect, since many signaling molecules are in low
abundance but have potent effects. Finding the causative tar-
gets could require focused genetic studies.
Second, we used commercially available g-secretasemodula-
tors that have been studied extensively and have undergone
clinical trials (Eriksen et al., 2003; Golde et al., 2013). In this
rapidly evolving field, it will ultimately be important to evaluate
next-generation modulators that are currently in pharmaceutical
development and not commercially available (Golde et al., 2013).
Although these modulators are more potent, many are also more
lipophilic, raising the caveat that even at low doses they could
accumulate inside the membrane and thus exacerbate, rather
than alleviate, cross-reactivity with rhomboid enzymes. Indeed,
extra caution is prudent with Alzheimer’s disease, because
prolonged drug regimens over a period of years (De Strooper
and Annaert, 2010; Golde et al., 2013) could amplify even a
modest induction of nonsubstrate processing by rhomboid pro-
teases. Our unexpected biochemical discovery with rhomboid
proteases could thus guide more directed animal studies to
characterize off-target effects of g-secretase modulators at the
organism level.
EXPERIMENTAL PROCEDURES
Chemicals
Small molecules were purchased from Sigma. Lipids were purchased from
Avanti Polar Lipids. NSAIDswere dissolved in dry dimethylsulfoxide (or ethanol
for DSC) and used immediately.
Plasmids
Genes were expressed from the pCMV promoter in pcDNA3.1 (Invitrogen).
Drosophila GFP-Spitz-FLAG, Delta-FLAG, Providencia GFP-TatA-FLAG, and
human GFP-APP-FLAG had a FLAG tag at their C-terminal ends, and all
except Delta also carried an N-terminal GFP as described previously (Moin
and Urban, 2012). Spitz was cotransfected with its transport factor, Star.
APP is normally cleaved by three different proteases in at least five different
sites. To decrease these confounding effects when studying rhomboid cleav-
age, we used human APP from residue 679 to its natural end (missing the alpha
and beta cleavage sites) preceded by GFP and the signal peptide from TGFa.
Cell Biology
HEK293T cells (ATCC), which are neuronal in origin (Shaw et al., 2002), were
transfected using X-tremeGENE HP (Roche), washed 22 hr posttransfection,
and incubated in serum-free media containing membrane-altering agents
(0.004% lyso-phospholipids or 2.5 mM mbCD) or NSAIDs (0.5 mM each,
with the exception of 0.1 mM for sulindac sulfide, or as specified otherwise)
for 18–24 hr. Cells were lysed in Laemmli buffer, resolved on 4%–20%
Tris-glycine SDS-PAGE gels, and subjected to quantitative western analysis
using infrared fluorescence (Li-Cor Biosciences). Cell viability was assessed
using trypan blue exclusion. Matrix-assisted laser desorption ionization
time-of-flight mass spectrometry was performed as described previously
(Moin and Urban, 2012).1246 Cell Reports 8, 1241–1247, September 11, 2014 ª2014 The AuDifferential Scanning Calorimetry
Small unilamellar vesicles were prepared from DMPC as described previously
(Dickey et al., 2013) and analyzed at 2 mg/ml in PBS with or without NSAIDs
that were freshly dissolved in ethanol. Samples were analyzed at 4C–40C
in a capillary VP-DSC (GE Healthcare) running at 10C/hr in high-sensitivity
mode.
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